Daily Cosmetic Research Analysis
Three studies stand out today: a prospective controlled study showing that preprocedural ultrasound reduces bruising in dermal filler procedures, a double-blind randomized trial linking stannous fluoride bioavailability to gingivitis control, and a 2-day intervention study demonstrating that restricting cosmetics use lowers endocrine-disrupting phenol exposure in adolescents who actively use personal care products. Together, they highlight how imaging, formulation chemistry, and exposure mitigat
Summary
Three studies stand out today: a prospective controlled study showing that preprocedural ultrasound reduces bruising in dermal filler procedures, a double-blind randomized trial linking stannous fluoride bioavailability to gingivitis control, and a 2-day intervention study demonstrating that restricting cosmetics use lowers endocrine-disrupting phenol exposure in adolescents who actively use personal care products. Together, they highlight how imaging, formulation chemistry, and exposure mitigation can improve cosmetic safety and outcomes.
Research Themes
- Imaging guidance to reduce adverse events in cosmetic procedures
- Formulation chemistry and bioavailability driving clinical oral health outcomes
- Public health impacts of endocrine-disrupting chemicals from cosmetics
Selected Articles
1. Integrating facial ultrasound into medical esthetics practice.
In a prospective, controlled quality improvement study (n=160), preprocedural facial ultrasound using a 16 MHz device significantly reduced bruising after dermal filler injections compared with standard care. Standardized protocols across three providers support feasibility, suggesting vascular mapping improves procedural safety.
Impact: Provides quantitative evidence that routine ultrasound guidance can reduce a common, patient-visible adverse event in aesthetic practice. This can change procedural workflows with minimal added cost or time.
Clinical Implications: Consider incorporating preprocedural facial ultrasound mapping to identify vessels and minimize bruising during dermal filler injections, particularly in high-risk areas. Training and access to mid-frequency probes (≈16 MHz) can standardize safer workflows.
Key Findings
- Preprocedural ultrasound (16 MHz) significantly reduced bruising compared with standard care in 160 patients.
- Standardized protocols across three experienced providers demonstrated feasibility in routine practice.
- Immediate postprocedure assessment showed benefit despite single-center limitations.
Methodological Strengths
- Prospective controlled design with equal-sized intervention and control groups (n=80 each).
- Standardized procedures across multiple providers using a defined device and outcome scale.
Limitations
- Single-center study with immediate postprocedure assessment; longer-term outcomes not reported.
- Non-randomized quality improvement design may allow selection bias.
Future Directions: Randomized, multicenter trials comparing ultrasound-guided vs. landmark-based injections with longer follow-up (ecchymosis duration, vascular complications) and cost-effectiveness analyses.
BACKGROUND: The increasing prevalence of dermal filler procedures has highlighted the need for enhanced visualization techniques to optimize outcomes and reduce complications. OBJECTIVE: To evaluate the impact of preprocedural ultrasound scanning on bruising outcomes in dermal filler treatments. METHODS: This prospective quality improvement study compared bruising outcomes between patients who received preprocedural ultrasound scanning (intervention group, n = 80) versus standard care (control group, n = 80) at a single center. The Bruising Visibility Scale was used to assess outcomes. Three experienced providers performed all procedures following standardized protocols, using a MindRay 16 MHz ultrasound device for the intervention group. RESULTS: Chi-square analysis revealed a statistically significant reduction in bruising incidence with preprocedural ultrasound scanning (χ LIMITATIONS: Single-center design and immediate postprocedure assessment timepoint. CONCLUSION: Preprocedural ultrasound scanning significantly reduces bruising in dermal filler procedures, suggesting improved vascular visualization may enhance procedural outcomes. These findings provide quantitative evidence supporting the integration of ultrasound guidance in esthetic practice.
2. A 3-month randomized trial evaluating the effects of stannous fluoride bioavailability on gingivitis.
In a double-blind, 4-arm RCT (n=120; 115 completers), a commercial 0.454% SnF2 dentifrice with high soluble tin (2,037 ppm) produced the largest reductions in gingival bleeding at 1 and 3 months versus all groups. An experimental SnF2 dentifrice with moderate soluble tin (592 ppm) outperformed a monofluorophosphate control, while a low-soluble tin SnF2 dentifrice (102 ppm) did not.
Impact: Links formulation bioavailability to clinical antigingivitis efficacy with supportive in vitro mechanistic alignment, informing product development and clinical recommendations.
Clinical Implications: When recommending SnF2 dentifrices for gingivitis control, prioritize formulations with higher soluble tin and demonstrated biofilm tin uptake to achieve superior bleeding reduction.
Key Findings
- Positive control SnF2 (soluble tin 2,037 ppm) had significantly fewer gingival bleeding sites vs all groups at 1 and 3 months (P≤0.04).
- Experimental SnF2 A (592 ppm soluble tin) reduced bleeding vs negative control (P≤0.041).
- Experimental SnF2 B (102 ppm soluble tin) did not differ from negative control (P≥0.438).
- In vitro tin uptake into biofilm and glycolysis inhibition paralleled clinical efficacy.
Methodological Strengths
- Double-blind, randomized, parallel-group design with active and negative controls.
- Predefined clinical endpoint complemented by in vitro mechanistic assays.
Limitations
- Three-month duration may not capture long-term gingivitis outcomes.
- Specific brand/formulation limits generalizability across all SnF2 products.
Future Directions: Longer-term RCTs comparing a spectrum of bioavailable tin levels, assessing plaque indices, microbiome shifts, and patient-reported outcomes.
PURPOSE: To assess the impact of formulation chemistry on gingivitis effects of two experimental 0.454% stannous fluoride (SnF2) dentifrices with low tin bioavailability versus positive and negative controls. METHODS: Adults with gingivitis were enrolled in this double-blind, parallel group, randomized clinical trial. Gingivitis was assessed with the Löe-Silness Gingivitis Index (LSGI) at baseline, 1 month, and 3 months. The four treatments were: experimental dentifrice A (0.454% SnF2, pH 4.7, soluble tin = 592 ppm), experimental dentifrice B (0.454% SnF2, pH 5.8, soluble tin = 102 ppm), positive control (0.454% SnF2 commercial dentifrice, soluble tin = 2,037 ppm), and negative control (0.76% sodium monofluorophosphate, soluble tin = 0 ppm). Participants brushed for 1 minute twice daily with their assigned dentifrice and a standard manual toothbrush. The primary clinical endpoint was number of gingival bleeding sites. In vitro analyses characterized tin uptake into biofilm and bacterial glycolysis. RESULTS: Of 120 participants randomized to treatment, 115 completed the study. Baseline mean number of bleeding sites (SD) was 35.11 (17.479). At 1 and 3 months, respectively, the mean was 19.52 and 16.64 for the positive control, 26.91 and 21.71 for Experimental dentifrice A, 31.01 and 27.59 for Experimental dentifrice B, and 33.20 and 29.59 for the negative control. At 1 and 3 months, the positive control showed significantly fewer bleeding sites versus all treatments (P≤ 0.04) and Experimental dentifrice A had significantly less bleeding versus the negative control (P≤ 0.041). Experimental dentifrice B was not significantly different from the negative control (P≥ 0.438) at either timepoint. Tin biofilm uptake and in vitro PGRM exhibited a similar trend. CLINICAL SIGNIFICANCE: SnF2 dentifrice formulation chemistry influences the level of antigingivitis efficacy, which was also reflected in tin bioavailability, tin uptake into biofilm, and bacterial glycolysis inhibition.
3. Parabens, bisphenols, and other environmental phenols exposure from cosmetics use in Korean adolescent girls: Findings from a 2-day intervention study.
Among 112 adolescent girls, frequent personal care product use was associated with higher urinary phenol biomarkers. In a 2-day cosmetic restriction among 74 participants, overall reductions were not significant; however, excluding non-users at baseline revealed substantial decreases in BPA (−32.7%) and benzophenones (−11.9% to −22.8%).
Impact: Provides empirical evidence that cosmetic use contributes to endocrine-disrupting phenol exposure in adolescents and that short-term restriction lowers exposure among active users, informing risk communication and policy.
Clinical Implications: Counsel adolescents and caregivers on product choices and usage patterns to reduce EDC exposure, prioritizing fragrance-free, paraben- and benzophenone-free products; consider targeted school-based interventions.
Key Findings
- Frequent PCP use correlated with higher urinary parabens (methyl, ethyl, propyl), BPA, and benzophenones at baseline.
- In the 2-day restriction (n=74), overall EDC reductions were not significant.
- Excluding baseline non-users (n=22) revealed significant decreases in BPA (−32.7%) and benzophenones (−11.9% to −22.8%).
Methodological Strengths
- Combines cross-sectional assessment with a short-term intervention in the same population.
- Focuses on a vulnerable demographic with objective biomarker measurements.
Limitations
- Non-randomized, short 2-day intervention limits causal inference and durability of effects.
- Self-reported product use may introduce misclassification; chemical mixtures not fully addressed.
Future Directions: Longer randomized interventions with product substitution, product-level chemical profiling, and health outcome tracking (e.g., endocrine endpoints).
Endocrine-disrupting chemicals (EDCs), such as bisphenols, parabens, and benzophenones, are commonly found in personal care products (PCPs) and pose a significant public health concern, particularly in adolescent girls. This study aimed to investigate the association between PCP use and urinary concentrations of environmental phenols in Korean adolescent girls, focusing on the potential role of PCPs as a major source of EDC exposure. A total of 112 female adolescents (aged 13-17 years) were recruited to examine the associations between urinary concentrations of parabens, bisphenols, benzophenones, and other environmental phenols and the self-reported frequency of PCP use (e.g., skincare products, sunscreen, cosmetics, and eye/lip products). In a subsequent two-day intervention restricting cosmetic use, involving a subpopulation of 74 participants, the changes in urinary chemical concentrations were assessed. Baseline findings showed an association between frequent PCP use and higher urinary concentrations of parabens (e.g., methyl, ethyl, and propyl parabens), bisphenol A (BPA), and benzophenone (e.g., benzophenone-1). After the two-day intervention, no significant reductions in EDCs concentrations were observed for the entire intervention participants (n = 74). However, when excluding adolescents with no baseline PCP use (n = 22), substantial reductions were shown in BPA (by 32.7 %), and benzophenones (by 11.9 %-22.8 %). This study contributes to the limited research on EDC exposure in adolescent populations and underscores the need for targeted public health interventions and policy measures to protect vulnerable populations from the potential health risks associated with EDC exposure.